Potomac Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Potomac Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,000	Closed	-$975K	–	83
2025 Q4	$975K	Buy	+8,000	New	+$917K	0.78%	32
2023 Q4	$1.03M	Hold	11,554	–	–	1.2%	23
2023 Q3	$844K	Hold	11,554	–	–	1.08%	23
2023 Q2	$961K	Sell	11,554 -846	-7%	-$70.8K	0.99%	28
2023 Q1	$945K	Hold	12,400	–	–	0.99%	30
2022 Q4	$1.03M	Buy	12,400 +1,900	+18%	+$154K	1.2%	21
2022 Q3	$833K	Sell	10,500 -700	-6%	-$59K	0.95%	31
2022 Q2	$832K	Buy	+11,200	New	+$841K	0.96%	35

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Potomac Capital Management's XBI Position: Q1 2026 in Review

Potomac Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 8,000 shares — an estimated $975K sold.

Potomac Capital Management first reported a position in XBI in Q2 2022 and held it in 8 quarters. The position peaked at $1.03M in Q4 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Potomac Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Potomac Capital Management sold 8,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $975K.
Potomac Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 8 quarters.
Potomac Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.03M in Q4 2023.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Potomac Capital Management's 13F filing for Q1 2026, filed 14 May 2026.